Literature DB >> 31256921

Substance P and fibrotic diseases.

Lei Peng1, George O Agogo2, Jianqiang Guo3, Ming Yan4.   

Abstract

Substance P (SP) is an undecapeptide encoding the tachykinin 1 (TAC1) gene and belongs to the tachykinin family. SP is widely distributed in the central nervous system and the peripheral nervous system. SP is also produced by nonneuronal cells, such as inflammatory cells and endothelial cells. The biological activities of SP are mainly regulated through the high-affinity neurokinin 1 receptor (NK-1R). The SP/NK-1R system plays an important role in the molecular bases of many human pathophysiologic processes, such as pain, infectious and inflammatory diseases, and cancer. In addition, this system has been implicated in fibrotic diseases and processes such as wound healing, myocardial fibrosis, bowel fibrosis, myelofibrosis, renal fibrosis, and lung fibrosis. Recently, studies have shown that SP plays an important role in liver fibrosis and that NK-1R antagonists can inhibit the progression of fibrosis. NK-1R receptor antagonists could provide clinical solutions for fibrotic diseases. This review summarizes the structure and function of SP and its involvement in fibrotic diseases.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Fibrotic disease; NK-1R; Substance P

Mesh:

Substances:

Year:  2019        PMID: 31256921     DOI: 10.1016/j.npep.2019.101941

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  4 in total

1.  Knockout of the Tachykinin Receptor 1 in the Mdr2-/- (Abcb4-/-) Mouse Model of Primary Sclerosing Cholangitis Reduces Biliary Damage and Liver Fibrosis.

Authors:  Ludovica Ceci; Heather Francis; Tianhao Zhou; Thao Giang; Zhihong Yang; Fanyin Meng; Nan Wu; Lindsey Kennedy; Konstantina Kyritsi; Vik Meadows; Chaodong Wu; Suthat Liangpunsakul; Antonio Franchitto; Amelia Sybenga; Burcin Ekser; Romina Mancinelli; Paolo Onori; Eugenio Gaudio; Shannon Glaser; Gianfranco Alpini
Journal:  Am J Pathol       Date:  2020-07-23       Impact factor: 4.307

2.  Substance P promotes the progression of bronchial asthma through activating the PI3K/AKT/NF-κB pathway mediated cellular inflammation and pyroptotic cell death in bronchial epithelial cells.

Authors:  Miao Li; Xiao Zhong; Wen-Ting Xu
Journal:  Cell Cycle       Date:  2022-06-26       Impact factor: 5.173

Review 3.  Therapeutic potential for targeting Annexin A1 in fibrotic diseases.

Authors:  Zhibin Yan; Xurui Cheng; Tao Wang; Xiangyu Hong; Gang Shao; Caiyun Fu
Journal:  Genes Dis       Date:  2022-06-18

4.  Blocking CTGF/CCN2 reduces established skeletal muscle fibrosis in a rat model of overuse injury.

Authors:  Mary F Barbe; Brendan A Hilliard; Mamta Amin; Michele Y Harris; Lucas J Hobson; Geneva E Cruz; Steven N Popoff
Journal:  FASEB J       Date:  2020-03-29       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.